Treatment of non-small-cell lung malignancies (NSCLCs) harboring major EGFR oncogenic mutations such as for example L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails because of the introduction of T790M mutation. purine primary N-9 position Earlier SAR data on cell lines indicated the decoration from the hydrophobic substituent in the N-9 site from… Continue reading Treatment of non-small-cell lung malignancies (NSCLCs) harboring major EGFR oncogenic mutations